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ABSTRACT 
 
Purpose 
To compare the outcomes of primary viscocanalostomy with trabeculectomy augmented 
with mitomycin C (MMC) in black South African patients with primary open-angle 
glaucoma (POAG). 
Method 
A prospective, randomized study was conducted over a four year period. Fifteen black 
South African patients with bilateral open-angle glaucoma requiring surgery that met the 
inclusion criteria and gave informed consent to participate in the trial were randomized to 
receive either a viscocanalostomy or a trabeculectomy with MMC in the first eye 
requiring surgery. The fellow eye then received the alternate procedure. Patients were 
followed up for two years postoperatively.  
Results 
There were no significant differences between the two surgical groups preoperatively. 
Twelve eyes in each group were followed for twenty-four months. In both groups the 
intraocular pressure (IOP) was significantly reduced post-operatively (p < 0.01) and the 
average number of medications used per eye was significantly reduced (p < 0.02). At 
twenty-four months, complete success (IOP less than or equal to 18mmHg without 
glaucoma medication and with no evidence of glaucoma progression) was seen in 75% of 
eyes undergoing trabeculectomy with MMC that completed the follow up, but in only 
 vii 
33% of eyes undergoing viscocanalostomy (p = 0.0498). Survival curves for both success 
and qualified success (IOP less than or equal to 18mmHg with glaucoma medications) in 
the two surgical procedures confirmed the superiority of trabeculectomy with MMC over 
viscocanalostomy.  
Conclusion 
Viscocanalostomy may offer some advantages because it is less invasive, but intraocular 
pressure control appears to be superior with trabeculectomy with MMC and this 
continues to be the filtering procedure of choice for the management of glaucoma in 
black South African patients.  
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PREFACE 
 
I first became interested in viscocanalostomies when Professor Robert Stegmann gave a 
presentation at a meeting of the Ophthalmological Society of South Africa in 
Johannesburg. His videos of his surgical technique were inspiring. I was particularly 
interested in the apparent avoidance of the requirement for mitomycin C (MMC) with his 
operation. Based on the professor’s excellent results I began to think that 
viscocanalostomy might be a safer alternative procedure to trabeculectomy with MMC in 
the patients at the St. John Eye hospital.  
 
I subsequently visited Professor Stegmann at Garankua Hospital and observed him 
operating. Once I had learnt the technique I decided to compare the procedure with 
trabeculectomy with MMC (the surgical standard in our hospital) because a literature 
search at the time revealed few randomised controlled trials comparing the two 
procedures. In particular no such trials had been conducted in black South African 
patients. 
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1.0 INTRODUCTION 
 
 
Trabeculectomy has long been considered the gold standard in the surgical treatment of 
glaucoma. It is, however, not without its problems: the outcome of the operation may be 
unpredictable and there are numerous potential complications like visual loss, long 
functional recovery, hypotony with a shallow anterior chamber, choroidal detachment, 
choroidal haemorrhage and cataract formation. Because of the often high failure rate in 
our predominantly black South African patients at the St. John Eye Hospital we routinely 
augment all our trabeculectomies with mitomycin-C (MMC), which produces its own set 
of complications. As a result of the problems with trabeculectomy there has been 
increasing interest in so-called “non-penetrating glaucoma surgery” of which 
viscocanalostomy is one type. This operation was pioneered by Professor Robert 
Stegmann and consists of a deep sclerectomy underneath a superficial scleral flap that 
“deroofs” the canal of Schlemm into which high density viscoelastic is injected. 
Stegmann’s hypothesis is that aqueous leaves the anterior chamber by percolating 
through Schlemm’s canal endothelium and Descemet’s membrane into the scleral “lake” 
created by the deep sclerectomy and from there it enters the widened cut ends of 
Schlemm’s canal and thus the aqueous veins and episcleral venous circulation.1 If this is 
the case then subconjunctival antimetabolites should be unnecessary and one could avoid 
their use, making the surgery safer still.  
 
Thus the rationale for this study was to determine if viscocanalostomy is an effective 
procedure in our setting at the St. John Eye Hospital, if the outcomes with 
 2 
viscocanalostomy are equivalent to a trabeculectomy augmented with MMC and if it does 
indeed have fewer complications than a trabeculectomy with MMC. 
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2.0 LITERATURE REVIEW  
 
Glaucoma Surgery 
 
Despite the fact that intraocular pressure (IOP) no longer forms part of the diagnosis of 
glaucoma, it is still recognised as an important risk factor for the presence or progression 
of glaucoma. The Advanced Glaucoma Intervention Study (AGIS)2  was a seminal work 
in highlighting the importance of sufficient pressure lowering in glaucoma. All current 
treatment modalities for glaucoma lower the IOP and thus reduce the IOP-related threat 
to vision. Surgery is the most effective way of reducing the IOP,3 but it is generally 
reserved for those patients in whom medical therapy has been unsuccessful, because of 
the morbidity associated with surgery. The challenge in glaucoma surgery is to find a 
procedure that is effective in lowering the IOP sufficiently without complications. 
 
Trabeculectomy with Mitomycin-C (MMC) 
 
Trabeculectomy was first described by Cairns in 1968.4 The procedure reduces the IOP 
through the creation of a sclerostomy that bypasses the trabecular meshwork and allows 
aqueous humour to flow out beneath a scleral flap and collect under the conjunctiva in a 
filtering bleb where it diffuse into periocular tissues and is subsequently reabsorbed into 
the vascular system. Trabeculectomy remains the most widely performed incisional 
surgical procedure for glaucoma worldwide and is considered the gold standard in the 
surgical treatment of glaucoma. Its effectiveness in lowering IOP has been 
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established,5,6,7 but many factors may affect the success rate. One such factor is African 
ancestry which may be a risk factor for postoperative scar formation and thus filtration 
failure.8 Inhibiting wound healing with a single peri-operative application of MMC (a 
cytotoxic agent that disrupts DNA, induces fibroblast death and inhibits fibroblast 
proliferation and migration)9 enhances the success rate of trabeculectomy.10   
 
Trabeculectomy is not without complications. In the initial postoperative phase visual 
loss, hypotony, anterior chamber shallowing, choroidal effusions, suprachoroidal 
haemorrhages and malignant glaucoma may occur.5,11 Late complications include 
prolonged hypotony associated with hypotony maculopathy and bleb-related infections.5 
The use of MMC has led to an increase in the incidence of these complications which 
may be associated with large avascular blebs.12,13 Trabeculectomy is also frequently 
associated with cataract formation.3,5 
 
Viscocanalostomy 
 
Viscocanalostomy was developed by Professor Robert Stegmann who perceived the need 
for a more successful procedure than trabeculectomy in black African patients.1 The 
procedure relies on a deep scleral dissection in the plane of the scleral spur and 
Schlemm’s canal to externalize and deroof Schlemm’s canal. The cut ends of Schlemm’s 
canal are then cannulated and high-viscosity sodium hyaluronate (Healon GV®) is 
injected into the canal.1 Stegmann’s hypothesis is that the IOP is lowered by aqueous 
humour percolating through Schlemm’s canal endothelium and Descemet’s membrane 
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into the scleral “lake” (the potential space created by the deep sclerectomy) and from 
there into Schlemm’s canal and thus the aqueous veins and episcleral venous circulation.1 
In theory, the absence of external filtration should obviate the need for inhibition of 
wound healing with MMC. 
 
Stegmann,1 in his retrospective review, reported an average IOP reduction of 64% with 
viscocanalostomy in black South African patients.  There were few complications in his 
series of 214 eyes. Specifically there were no flat chambers or choroidal detachments and 
there was no cataract development. Only 5% of his patients had subconjunctival bleb 
formation. The low incidence of complications has been duplicated in prospective studies 
by Carassa,14 Sunaric-Mégevand,15 Luke16 and Shaarawy17 with varying success rates. 
 
Comparison of trabeculectomy with MMC with viscocanalostomy in open-angle 
glaucoma 
 
Several investigators have compared the outcomes of trabeculectomy with 
viscocanalostomy,18,19,20,21,22 but there are few randomised prospective trials comparing 
trabeculectomy with MMC with viscocanalostomy. 
 
Kobayashi et al.23 compared trabeculectomy with MMC to viscocanalostomy in 50 eyes 
of 25 patients. After one year’s follow-up 88% of the trabeculectomy eyes and 64% of 
the viscocanalostomy eyes had achieved an IOP under 20mmHg. The mean final IOP was 
4.5mmHg lower in the eyes that underwent trabeculectomy with MMC. 
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O’Brart et al.24 compared trabeculectomies with antimetabolites (either 5-fluorouracil or 
MMC based on a risk factor for failure score) with viscocanalostomies in 50 eyes 
followed for between 12 and 24 months. At 12 months of follow up 100% of the 
trabeculectomy eyes had an IOP under 21mmHg (with or without medical therapy) 
whereas only 64% of the viscocanalostomy eyes were successful according to the same 
criteria. This significant difference held true for complete success (IOP of 15mmHg or 
less without glaucoma medication). In the trabeculectomy group at one year this was 
achieved in 76% of the patients whereas it was only achieved in 26% of the 
viscacanalostomy group. There were more transient complications in the trabeculectomy 
group and more cataracts developed in this group. 
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3.0 PATIENTS AND METHODS 
 
 
This prospective randomized trial enrolled fifteen patients with bilateral open angle 
glaucoma requiring surgery to both eyes. The diagnosis of glaucoma was based on the 
appearance of the optic nerve head and the presence of visual field defects. The 
requirement for surgery was an intraocular pressure (IOP) of greater than 18mmHg on 
maximum tolerated medical therapy or glaucoma progression on maximum tolerated 
medical therapy. Written informed consent was obtained from each participant. 
 
Patients were excluded if they had had previous glaucoma surgery or if they had angle 
closure, neovascular glaucoma, post-traumatic glaucoma or dysgenetic glaucoma.  
 
Preoperatively, the patients were questioned on the use of antiglaucoma medications, 
coexisting systemic or ocular disease, use of systemic medication, and previous 
intraocular surgical or laser procedures. The baseline ophthalmological examination 
consisted of a Snellen best-corrected visual acuity for distance, a visual field test, slit-
lamp examination, Goldmann applanation tonometry, gonioscopy and dilated 
fundoscopy. The type of glaucoma and the lens status were documented. 
 
The patients were randomized into either a trabeculectomy with MMC or a 
viscocanalostomy in the first eye followed by the other procedure in the second eye. The 
author performed all the operations. 
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Surgical Technique 
 
In both procedures the technique involved a fornix based conjunctival flap, vasopressin 
(POR-8®) was used for haemostasis and a 5mm by 5mm parabolic scleral flap was 
fashioned which was dissected into clear cornea (see Figure 3.1). 
 
 
Figure 3.1: Dissection of a parabolic scleral flap 
 
In the trabeculectomies 0,25mg/ml of mitomycin-C was applied with a sponge under the 
conjunctival flap for one minute before dissecting the scleral flap. This area was then 
irrigated with balanced salt solution (BSS®). After lifting the flap a 2mm by 2mm 
sclerostomy was followed by a peripheral iridectomy. The scleral flap was sutured using 
interrupted 10-0 prolene sutures and the conjunctiva was closed using 8-0 vicryl sutures. 
 
In the viscocanalostomies a 4mm by 4mm deep scleral flap was dissected under the initial 
parabolic flap to deroof the canal of Schlemm. The dissection was continued anteriorly to 
form a Descemet’s window (see Figure 3.2).  
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Figure 3.2: Deroofing of the canal of Schlemm with a deep scleral flap 
 
A 150µm cannula (viscocanalostomy cannula) was then inserted into the ostia of 
Schlemm’s canal, both left and right, and Healon GV® was injected into the canal for 4 to 
6mm on each side. The scleral flap was sutured using interrupted 10-0 prolene sutures 
and the conjunctiva was closed using 8-0 vicryl sutures in the same way as with the 
trabeculectomies. 
 
Post-operatively the treatment regimen was the same in both surgical procedures and 
consisted of: 
• Topical prenisone acetate given two hourly for the first week then four times a day 
for three weeks, then tapering over the next two months in combination with 
• Topical homatropine given twice daily for the first week 
• Topical chloromycetin drops given three times daily for the first week. 
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Follow up 
 
Patients were followed for twenty-four months post-operatively. They were examined at 
one day, one week, one month, and three months post-operatively and then three monthly 
thereafter. At each visit Snellen best corrected visual acuity, IOP, anterior chamber 
activity, appearance of the bleb, lens appearance, optic disc status and number of 
antiglaucoma agents required to achieve optimal levels of IOP were documented. At 
months six, twelve, eighteen and twenty four the patients had visual fields, gonioscopy 
and stereo disc assessments to exclude glaucoma progression. Extra visits were scheduled 
as clinically warranted. The incidence of any complications and the requirement for any 
additional procedures was documented. 
 
Outcome measures 
 
The main outcome measure was the intraocular pressure.  
 
Success was defined as an IOP of less than or equal to 18mmHg without glaucoma 
medication and with no evidence of glaucoma progression whereas a qualified success 
was an IOP of less than or equal to 18mmHg with glaucoma medication but with no 
evidence of glaucoma progression.  
 
A qualified failure was defined as an IOP of greater than 18mmHg with glaucoma 
medication but with no evidence of glaucoma progression and failure was an IOP of 
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greater than 18mmHg with evidence of glaucoma progression or requiring further 
glaucoma surgery. Bleb needling procedures and laser goniopunctures were not 
considered as failures. 
 
A secondary outcome measure was the number of glaucoma medications used per eye. 
 
Statistical testing 
 
Paired t tests were used to compare continuous variables between the groups such as IOP. 
 
The Wilcoxon matched pairs signed rank test was used to compare count data that was 
not normally distributed such as the difference in number of medications.  
 
Fisher’s exact test was used to compare categorical data. 
 
Kaplan-Meier survival analyses were carried out using the definitions of success and 
qualified success as criteria. Comparisons between groups were done by the log-rank test. 
 
A Cox model was used to investigate the effect of certain variables (covariates) on the 
success of surgery. 
 
All tests were two-tailed and p-values of less than or equal to 0.05 were taken to be 
significant (95% confidence level) unless otherwise indicated. 
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4.0 RESULTS  
 
 
Fifteen South African black patients with bilateral open-angle glaucoma were enrolled in 
the study. The demographics of the patients are recorded in Table 4.1.  
 
Six of the patients were male, and nine were female. The mean age was 65years (range 
49 to 75 years). Six patients had a glaucoma diagnosis of exfoliative glaucoma and nine 
had primary open-angle glaucoma. Nine of the patients were hypertensive on treatment; 
four of these patients were also diabetic. 
 
Table 4.1: Patient demographics and study diagnosis (XFG = exfoliative glaucoma; 
POAG = primary open-angle glaucoma, HT = hypertensive) 
 
Patient Sex Age Diagnosis Medical history 
A Female 73 XFG HT, Arthritis 
B Male 68 XFG HT, Diabetic 
C Female 52 POAG Nil 
D Female 49 POAG HT 
E Female 69 XFG HT 
F Male 63 POAG Nil 
G Female 71 POAG HT, Diabetic 
H Male 75 XFG HT 
I Male 69 XFG Nil 
J Female 57 POAG Nil 
K Male 67 POAG HT 
L Male 61 POAG Nil 
M Female 62 POAG HT, Diabetic 
N Female 69 XFG HT 
O Female 60 POAG Asthmatic 
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A trabeculectomy with MMC was performed in fifteen eyes and a viscocanalostomy was 
performed in the fellow fifteen eyes. The preoperative IOP and the number of 
medications per eye for these two surgical groups were similar (Table 4.2). 
 
Table 4.2: Preoperative IOP and number of medications in the eyes that underwent 
trabeculectomy with MMC and viscocanalostomy 
 
Surgery Trabeculectomy Viscocanalostomy 
 
Average IOP (mm Hg) * 23.3 ± 2.3 26.4 ± 3.0 
Number of subjects 15 
p-value (paired sample t-test) 0.078 (not significant) 
p-value (Wilcoxon matched pairs test) 0.097 (not significant) 
 
Average number of medications * 2.1 ± 0.2 2.0 ± 0.2 
Median number of medications ** 2 (2 – 2) 2 (2 – 2) 
Number of subjects 15 
p-value (Wilcoxon matched pairs test) - (not significant) 
* mean ±  95% confidence intervals 
** median (25th – 75th percentile range) 
 
In comparing the preoperative IOP in these two surgical groups both the paired sample t-
test and the Wilcoxon matched pairs test were used. The paired sample t-test could be 
used because the differences between the trabeculectomy and viscocanalostomy values 
were approximately normally distributed. The results were confirmed using the non-
parametric Wilcoxon matched pairs test which required no assumptions about the 
distribution of the data to be met. 
 
Comparing the number of medications used per eye in each surgical group required the 
Wilcoxon matched pairs test because the paired differences were not normally 
distributed. There were only two non-zero differences (most of the eyes were on dual 
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therapy) therefore it was not possible to calculate a p-value, but the difference is not 
significant. 
 
Preoperatively (Table 4.3) four eyes in each group had lens opacities (in three instances 
in the same patients), two of the trabeculectomy eyes were pseudophakic as was one of 
the viscocanalostomy eyes. One of the pseudophakic eyes in the trabeculectomy group 
(patient H) had had a complicated extracapsular cataract extraction which had resulted in 
prolonged post-operative intraocular inflammation – the eye was not active at the time of 
surgery, but this may have been an additional risk for failure. None of the patients had 
had previous glaucoma laser procedures. 
 
 
 
Table 4.3: Preoperative findings in the eyes that underwent trabeculectomy with MMC 
and viscocanalostomy. The letters (A-O) refer to the individual patients as recorded in 
Table 4.1 
 
  Trabeculectomy No. % Viscocanalostomy No. % 
Preoperative findings 
 
 
 
 
 
 
 
15 100  15 100 
Arcus Senilis 
Pingueculum 
Lens opacities 
F 
A,B,C,D,E,I,K 
A,B,E,M 
1 
7 
4 
6.7 
46.7 
26.7 
F 
A,B,C,D,E,I,K,O 
A,E,H,M 
1 
8 
4 
6.7 
53.3 
26.7 
Pseudophakic H,G 2 13.3 G 1 6.67 
Intraocular 
inflammation 
 
H 1 6.7     0 
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Two of the patients (patients F and N) defaulted before the completion of the study 
period and patients B (trabeculectomy first) and I (viscocanalostomy first) defaulted after 
completing the study period of twenty four months of follow-up after surgery to their first 
eye, but before completing this period with the fellow eye. Thus twenty-four eyes (twelve 
eyes that had trabeculectomies with MMC and twelve eyes that had viscocanalostomies) 
were followed for the complete two year period. 
 
The IOP results for the study period are summarized in Table 4.4 and illustrated 
graphically in Figure 4.1. IOP data were included up to twenty-four months after surgery 
even if patients were placed on antiglaucoma medications or had another procedure to 
lower IOP. As a result of this, after one month post-operatively the conditions between 
the matched eyes differ making comparisons difficult. 
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Table 4.4: IOP results for the study period in the eyes that underwent trabeculectomy 
with MMC and viscocanalostomy 
 
 Average IOP (mm Hg) ± 95% confidence interval  
Time after surgery Trabeculectomy with MMC Viscocanalostomy 
Pre-operative 23.3 ± 2.3 26.4 ± 3.0 
1 day 17.3 ± 4.4 10.3 ± 3.5 
1 week 12.4 ± 4.5 14.4 ± 4.1 
1 month 11.7 ± 4.1 17.8 ± 4.1 
3 months 11.4 ± 2.0 15.7 ± 2.5 
6 months 9.8 ± 1.7 15.9 ± 2.9 
9 months 11.2 ± 1.7 15.0 ± 2.2 
12 months 11.6 ± 2.2 14.9 ± 1.9 
15 months 12.7 ± 2.3 15.2 ± 1.5 
18 months 12.5 ± 2.7 15.8 ± 2.0 
21 months 13.5 ± 2.7 15.2 ± 2.0 
24 months 14.1 ± 3.8 16.5 ± 2.0 
 
 
Figure 4.1: Average IOP in mmHg on the y-axis plotted against the time after surgery on 
the x-axis in the eyes that underwent trabeculectomy with MMC (Trabec) and 
viscocanalostomy (Visco). Error bars represent 95% confidence intervals for the average 
IOP 
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The median number of medications per eye over the study period is recorded in table 4.5 
and illustrated graphically in Figure 4.2. The median was used rather than the average 
because the data are not continuous and are not normally distributed. Medication data 
were included up to 24 months after surgery even if patients had another procedure to 
lower IOP. 
 
 18 
Table 4.5: Median number of medications per eye for the study period in the eyes that 
underwent trabeculectomy with MMC and viscocanalostomy 
 
 Median number of medications  (25th – 75th percentile) 
Time after surgery Trabeculectomy with MMC Viscocanalostomy 
Preoperative 2   (2 – 2) 2   (2 – 2) 
1 day 0   (0 – 0) 0   (0 – 0) 
1 week 0   (0 – 0) 0   (0 – 0) 
1 month 0   (0 – 0) 0   (0 – 0) 
3 months 0   (0 – 0) 0   (0 – 0) 
6 months 0   (0 – 0) 0   (0 – 0) 
9 months 0   (0 – 0) 0   (0 – 0) 
12 months 0   (0 – 0) 0   (0 – 0) 
15 months 0   (0 – 0) 0   (0 – 1) 
18 months 0   (0 – 0) 0   (0 – 1) 
21 months    0   (0 – 0.5)    1   (0 – 1.5) 
24 months    0   (0 – 0.5)    0.5   (0 – 1) 
 
 
 
Figure 4.2: Median number of medications used per eye on the y-axis plotted against the 
time after surgery on the x-axis in the eyes that underwent trabeculectomy with MMC 
(Trabec) and viscocanalostomy (Visco). The hashed lines represent the 25th and 75th 
percentiles of the data 
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In both groups the IOP was significantly reduced post-operatively and the median 
number of medications used per eye was significantly reduced (Table 4.6). 
 
Table 4.6: Paired sample comparisons of IOP (using parametric and non-parametric 
paired-sample tests) and number of medications per eye preoperatively (Pre-op) and at 
the end of the study period (24m) in eyes that had trabeculectomy with MMC and those 
that had viscocanalostomy 
IOP (mmHg)* Number of medications ** Surgery 
Pre-op 24m Pre-op 24m 
23.3 ± 2.3 14.1 ± 3.8 2 (2 – 2) 0 (0 – 0.5) Trabeculectomy 
               p = 0.012 *** 
               p = 0.003 (t-test)  
               n =12 
                 p = 0.003 
 
                 n=12 
26.4 ± 3.0 16.5 ± 2.0 2 (2 – 2) 0 (0 – 1) Viscocanalostomy 
               p = 0.003 
               p = 0.002 (t-test) 
               n = 12 
                 p = 0.012 
 
                 n=12 
 * mean ±  95% confidence intervals 
 ** median (25th – 75th percentile range) 
 *** p-value refers to Wilcoxon matched pairs test unless otherwise indicated 
 
 
Table 4.7 shows the outcome for each patient in the two surgical groups in terms of the 
defined criteria for success, qualified success, qualified failure and failure. With one 
exception (H) and the patients where we cannot comment because of dropouts, the 
trabeculectomy with MMC outcome was the same or better than the viscocanalostomy 
outcome.  
 
Table 4.8 summarises this data for the group as a whole. 
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Table 4.7: The surgical outcome for each patient in the eye that had a trabeculectomy 
with MMC and in the eye that had the viscocanalostomy. S = success, QS = qualified 
success, F = failure, QF = qualified failure, X = dropped out before completion of the 
study period 
Patient Trabeculectomy with MMC Viscocanalostomy 
A S QS 
B S X 
C S QF 
D S F 
E S S 
F X X 
G S S 
H F QS 
I X F 
J QS F 
K S QF 
L S S 
M QS QS 
N X X 
O S S 
 
Table 4.8: The surgical outcome at the end of the study period in the two surgical groups 
Surgery Trabeculectomy & MMC Viscocanalostomy 
Success   9      (60 %)   4     (26.7%) 
Qualified success   2      (13.3%)   3     (20%)    
Qualified failure   0      (0%)   2     (13.3%) 
Failure   1      (6.7%)   3     (20%)    
Dropped out of study   3      (20%)   3     (20%) 
Total   15    (100%)   15   (100%) 
 
 
 
 21 
Fisher’s exact test analysis of the  contingency table of complete success versus qualified 
success, qualified failure or failure (Table 4.9) shows a significant difference between the 
two surgical procedures (p = 0.0498). In this group of patients trabeculectomy with MMC 
is superior to viscocanalostomy in reducing the IOP to 18mmHg or less without 
additional glaucoma medication or progression of the glaucoma. 
 
Table 4.9: Contingency table analysis of complete success versus qualified success, 
qualified failure or failure at the end of the study period in the two surgical groups 
Surgery Trabeculectomy Viscocanalostomy Total 
Success 9 4 13 
Qualified success, qualified failure or 
failure 3 8 11 
Total 12 12 24 
Fisher’s exact test, one-tailed: p = 0.0498 
 
Figures 4.5 and 4.6 show the Kaplan-Meier survival curves for complete success (Figure 
4.3) and qualified success (Figure 4.4) in the two procedures. The surgical procedures 
were standardized and performed by a single surgeon, so it was assumed that the 
probability of survival was the same for early and late recruits into the study. The patients 
who did not complete the study were assumed to have the same probability of survival as 
those subjects who completed the study period. The reasons for failure to complete the 
study are not known (the patients did not return for their follow-up appointments), but it 
is assumed that it was unrelated to the surgical procedures.  
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Figure 4.3: Comparing trabeculectomy with MMC (trabec) and viscocanalostomy 
(visco) outcomes. Kaplan-Meier survival curves for maintaining IOP at 18mmHg or less 
without medication. Complete = patient’s eye required medical therapy; Censored = 
dropped out or end of study. Log rank test, p = 0.044 
 
 23 
 
 
 
Figure 4.4: Comparing trabeculectomy with MMC (trabec) and viscocanalostomy 
(visco) outcomes. Kaplan-Meier survival curves for maintaining IOP at 18mmHg or less 
with additional glaucoma medication. Complete = patient’s eye required medical therapy; 
Censored = dropped out or end of study. Log rank test, p = 0.059 
 
 
 
 
The logrank test on the Kaplan-Meier survival curves shows that the two surgical 
procedures are significantly different for complete success at the 95% confidence level (p 
= 0.044) and for qualified success at the 90% confidence level (p = 0.059). 
 
A Cox model was used to investigate the effect of certain variables (covariates) on the 
success of surgery. The result of this proportional hazard analysis is given in Table 4.10. 
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Univariate analyses were first conducted for each factor with the intention of including 
those covariates having an effect with statistical significance of p<0.1 in a multiple 
regression model. 
 
Table 4.10: Results of Cox’s regression analysis for the two success criteria. Complete 
success = IOP ≤ 18mmHg without medication; Qualified success = IOP ≤ 18mmHg with 
medication 
  
Variable Complete Success Qualified Success 
 Hazard Ratio p-value Hazard Ratio p-value 
First Surgery 0.84 0.77 0.82 0.80 
Pseudophakia 0.94 0.95 1.47 0.73 
Gender 0.95 0.93 0.50 0.40 
Age 1.00 0.92 0.96 0.45 
Diagnosis 0.84 0.78 1.07 0.94 
Surgery 3.48 0.067 6.06 0.10 
 
 
Despite the small numbers (reflected in the p-values), the analysis confirms the 
significance of the type of surgical procedure on the success rates. The order of surgery, 
the presence of preoperative pseudophakia, gender, age and glaucoma diagnosis did not 
have a significant influence on the outcome of the surgery, however with a larger sample 
size this might change. 
 
Complications  
 
The intra-operative, early and late postoperative complications in each surgical group are 
recorded in table 4.11. 
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Table 4.11: Intra-operative, early and late complications and additional procedures 
required in the eyes that had trabeculectomy with MMC tabulated with those that 
underwent viscocanalostomy. The letters (A-O) refer to the individual patients as 
recorded in table 4.1 
  Trabeculectomy No. % Viscocanalostomy No. % 
Intraoperative 
complications             
 Microperforation of 
canal of Schlemm   0 0 E,F,N 3 20 
Early complications             
 Hypotony (IOP<6 
mmHg) G,J 2 13.3 E,F,I 3 20 
 Anterior chamber 
shallowing G,J 2 13.3   0 0 
 Choroidal detachments   0 0   0 0 
 Overlarge blebs K 1 6.7   0 0 
 IOP spike D,L 2 13.3   0 0 
Late complications             
 Avascular blebs A,C,D 3 20   0 0 
 Overlarge/overhanging 
blebs C,K,L 3 20   0 0 
 Hypotony (IOP<6 
mmHg) A,F 2 13.3   0 0 
 Late bleb leak    0 0   0 0 
 Eyes requiring cataract 
surgery A,B,F,I,K 5 33.3 A,H 2 13.3 
Additional procedures             
 Ocular Massage C,D,E,K,L,M,O 7 46.7 G 1 6.7 
 Cataract surgery A,B,F,I,K 5 33.3 A,H 2 13.3 
 YAG goniotomy   0 0 A,B,C,D,G,J,K,L,M 9 60 
 Bleb needling M 1 6.7 B,K 2 13.3 
 Suturelysis G,H,O 3 20   0 0 
 Flap revision G,J 3 20   0 0 
 Repeat glaucoma 
surgery for failure H 1 6.7 D,I,J 3 20 
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Intra-operatively the surgery was uneventful in both groups. In three of the 
viscocanalostomy eyes a diagnosis of microperforation of the canal of Schlemm was 
made based on the observation of loss of convexity and an increase in the egress of fluid 
through the Descemet's window. 
 
Two of the trabeculectomy eyes (13.3%) were hypotonous on day one with shallow 
anterior chambers which required flap resuturing. Three of the viscocanalostomy eyes 
(20%) had IOPs less than 5mmHg on day one, but the anterior chambers were well 
formed, there were no choroidal detachments and the hypotony resolved without 
intervention or consequences. On the first post-operative day, seven of the 
trabeculectomy eyes (46.7%) required ocular massage to bring the IOP to acceptable 
levels. Two of these patients had a post-operative IOP spike which was controlled with 
ocular massage. Only one (13.3%) of the viscocanalostomy eyes required ocular 
massage. 
 
Before the one month follow up visit three of the trabeculectomy eyes required 
suturelysis to bring the IOP down to below 18mmHg (only one of these eyes had required 
ocular massage on day one). 
 
Over the study period five eyes in the trabeculectomy group (33.3%) and two in the 
viscocanalostomy group (13.3%) required cataract surgery for deteriorating visual acuity. 
Both of the eyes requiring cataract surgery in the viscocanalostomy group had cataracts 
preoperatively that worsened during the study period. In contrast three of the 
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trabeculectomy eyes had clear lenses preoperatively but developed cataracts after the 
glaucoma surgery – presumably as a result of it. Patients E and M had bilateral lens 
opacities preoperatively, but the cataracts did not progress during the study period in 
either the viscocanalostomy or the trabeculectomy eyes. 
 
Three eyes in the trabeculectomy group had symptomatic blebs compared to none in the 
viscocanalostomy group. All the functioning viscocanalostomy eyes had conjunctival 
blebs, but the blebs were more diffuse and shallower than those seen in the 
trabeculectomy eyes. Nine (60%) of the viscocanalostomy eyes required Nd:YAG laser 
goniopuncture. Two of the complete successes (50%) in the viscocanalostomy group had 
had YAG goniotomy procedures. One eye in the trabeculectomy group and two in the 
viscocanalostomy group underwent a bleb needling procedure.   
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 5.0 DISCUSSION 
The results of this prospective, randomized study indicate that both trabeculectomy with 
MMC and viscocanalostomy are effective procedures (they both significantly lower the 
IOP and reduce the requirement for antiglaucoma medications) for the control of IOP in 
open angle glaucoma in black South African patients. The results further indicate that 
trabeculectomy with MMC is superior to viscocanalostomy in controlling IOP in this 
group. The mean IOP levels were lower in the trabeculectomy group from month one 
postoperatively, however it is difficult to comment accurately on these findings because 
some eyes were being treated medically with antiglaucoma medication. Complete success 
rates (IOP less than or equal to18 mm Hg with no glaucoma medications) at 24 months 
were significantly better with trabeculectomy augmented with MMC. In addition, the 
number of eyes receiving antiglaucoma medications and the average number of 
medications per eye required postoperatively in order to maintain an IOP at 18 mm Hg or 
lower were less with trabeculectomy with MMC. Kaplan-Meier survival analysis with log 
rank to compare and Cox proportional hazard method confirmed the superiority of 
trabeculectomy with MMC in achieving a successful outcome. 
 
A review of the current literature supports these findings. Prospective, randomized 
studies comparing trabeculectomy without antifibrosis with viscocanalostomy 
demonstrated higher success rates in the trabeculectomy treatment group.18,19,20,21,22  Two 
further prospective randomized trials compared trabeculectomy augmented with 
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antimetabolites with viscocanalostomy and, in common with my study, found the 
trabeculectomy treatment arm to be more successful in lowering IOP. 23,24 
 
The mechanism of viscocanalostomy in its ability to reduce IOP is uncertain. Stegmann 1 
postulated that IOP was lowered by aqueous humour percolating through Schlemm’s 
canal endothelium and Descemet’s membrane into the scleral “lake” (the potential space 
created by the deep sclerectomy) and from there into previously non-functional sectors of 
Schlemm’s canal and to collector chanels. Tamm et al.25 performed viscocanalostomies 
on rhesus monkeys and they, in contrast, suggest that the most likely cause of the 
reduction in outflow resistance after this type of surgery is a focal disruption of the inner 
wall endothelium and opening of the juxtacanalicular or cribriform region of the 
trabecular meshwork which they found on electron microscopy. Injection of viscoelastic 
into Schlemm’s canal may not only dilate the canal, but it may also disrupt the walls of 
the canal and the adjacent trabecular layers. This procedure may thus act as a 
trabeculotomy. Other possible mechanisms that have been proposed are external filtration 
from the scleral “lake” to the subconjunctival space and uveoscleral absorption directly 
from the scleral “lake”.23,24 In all the viscocanalostomy eyes in this report with successful 
drainage, there was evidence of subconjunctival drainage of aqueous, confirmed by the 
presence of conjunctival drainage blebs (Figure 5.1). In eyes without successful drainage 
these changes were not evident. This is in contrast to Stegmann,1 who reported bleb 
formation in only five percent of his patients, but is supported by O’Brart’s findings.24  
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Figure 5.1: Subconjunctival blebs following viscocanalostomies 
Such findings suggest that in the viscocanalostomy technique used in this study (which 
although based on Stegmann’s technique was not identical to his technique – the 
operations were not under general anaesthetic and the author was not as rigorous as he in 
making the sutured scleral flaps water-tight), the subconjunctival route is the main 
drainage pathway. This may be one of the reasons for the higher success rate in the 
trabeculectomy eyes. Black patients are at higher risk for failure of trabeculectomies 
without antifibrosis;8 if this viscocanalostomy technique relies on subconjunctival 
drainage it follows that this technique should also be augmented with MMC. O’Brart et 
al.24 came to a similar conclusion and they went on to perform a second prospective, 
randomized trial where antimetabolites were used as an adjunct in both operative 
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groups.26 Disappointingly they still found that trabeculectomy was the superior procedure 
for IOP lowering.  
 
Viscocanalostomy has the theoretical advantage of being less invasive than 
trabeculectomy. This advantage is borne out in this group by fewer early complications 
such as anterior chamber shallowing associated with hypotony and, at the other end of the 
spectrum, IOP spikes. There was also a reduced incidence of postoperative cataract 
formation with viscocanalostomy. This is a common finding in other studies comparing 
these two procedures.24,26 The early complications were managed with effective 
intervention. Cataract surgery returned the visual acuity to preoperative levels and had no 
impact on bleb survival. 
 
In this study the viscocanalostomy eyes generally had shallower and more diffuse blebs 
than the trabeculectomy eyes where there was a higher incidence of avascular and 
overlarge blebs. This may be related to the use of MMC in the trabeculectomy eyes. 
 
O’Brart et al.26 found that encysted blebs and the requirement for bleb needling was more 
common in trabeculectomy eyes. This was not the case in this series. Many of the 
viscocanalostomy eyes, however, required and responded to Nd:YAG laser 
goniopuncture for additional IOP lowering during the study period. Stegmann1 did not 
perform goniopunctures in his series, but many other investigators do with varying 
frequency. In this study 60% of the viscocanalostomy eyes had a goniopuncture 
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procedure. This is similar to the findings of Kobayashi et al.23  where 56% of the 
viscocanalostomy group received a goniopuncture at an average of four weeks 
postoperatively, but is more than the incidence reported by O’Brart,24,26 Sunaric-
Mégevand,15 and Shaarawy.17 This reliance on Nd:YAG laser technology may limit the 
appropriateness of this intervention to patients from urban areas with easy access to 
tertiary health care. 
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6.0 CONCLUSION 
 
 
Viscocanalostomy was first described in a population of predominantly black South 
African patients, the same as this study population; however the procedure was not 
compared with the gold standard of trabeculectomy with antimetabolites.1 This 
prospective randomized study sought to compare these two procedures in this population 
group over a two year time period. The study is limited by a small sample size, but the 
results indicate that viscocanalostomy is an effective way of decreasing the IOP in 
patients with open angle glaucoma; however a trabeculectomy augmented with 
mitomycin C was the more successful procedure in this sample.  
 
Viscocanalostomy tends to have fewer postoperative complications and less symptomatic 
blebs, but many of the patients require laser goniopuncture during the postoperative 
period and may require more follow-up visits.  Viscocanalostomy is associated with less 
cataract formation, but significant problems permanently impairing vision did not occur 
with either technique. 
 
On examination of the eyes in this study in which successful viscocanalostomy was 
performed, it was found that they all had shallow subconjunctival blebs. Subconjunctival 
drainage of aqueous may be the main mechanism of aqueous drainage in these eyes, so 
the procedure should probably also be augmented with mitomycin C in a population such 
as this one that has such a high failure rate for glaucoma drainage procedures. 
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Although viscocanalostomy offers some advantages because it is less invasive, 
intraocular pressure control appears to be far superior with trabeculectomy with MMC 
and this continues to be the filtering procedure of choice for the management of 
glaucoma in black South African patients.  
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